• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu
VIEW ALL RESEARCH-GROUP

Molecular signaling
Viñals’s lab

DESCRIPTION

Our research is focused on the study of the implication of intracellular signaling cascades driving to pathological situations in cancer and vascular diseases.

The molecular signaling cascades that take place inside the cells are essential to respond to changes in their environment or to alter their homeostasis, for example, at the level of cell proliferation, movement, growth or metabolism. Understanding how these mechanisms of signal transduction work can explain how biological processes are controlled in a normal physiological context, but also, the alterations that take place in many pathologies. Our group investigates this in two pathological contexts: The first is ovarian epithelial cancer, where we study the pathways involved in metastasis and the mechanisms of resistance to therapies. A second context is a rare vascular disease, HHTs, in which, in collaboration with the group led by Toni Riera (Hospital de Bellvitge), we study which signaling pathways are altered in patients with mutations that cause this disease, and how treat them with new drugs.

Group members

Francesc Viñals

Group leaders

Group Leader

Agnès Figueras

Researchers

Núria Gendrau Sanclemente

PhD student

Ferran Medina Jover

PhD student

José Luís Rocamora

PhD student

Tianyu Dai

PhD student

Publications

ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation

17 de February de 2018/in Viñals's lab/by miguel

Arterioscler Thromb Vasc Biol. 2018 May;38(5):1216-1229. doi: 10.1161/ATVBAHA.118.310760. Epub 2018 Feb 15. ABSTRACT OBJECTIVE: ALK1 (activin-receptor like kinase 1) is an endothelial cell-restricted receptor with high affinity for BMP (bone morphogenetic protein) 9 TGF-β (transforming growth factor-β) family member. Loss-of-function mutations in ALK1 cause a subtype of hereditary hemorrhagic telangiectasia-a rare disease characterized by vasculature […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-02-17 11:00:002018-02-17 11:00:00ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation

A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination

18 de November de 2017/in Viñals's lab/by miguel

Mol Cancer Ther. 2018 Feb;17(2):532-543. doi: 10.1158/1535-7163.MCT-17-0643. Epub 2017 Nov 16. ABSTRACT Epithelial ovarian cancer is characterized by a low recovery rate because the disease is typically diagnosed at an advanced stage, by which time most patients (80%) already exhibit disseminated neoplasia. The cytokine receptor CXCR4 has been implicated in the development of metastasis in […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-11-18 11:00:002017-11-18 11:00:00A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination

TGFβ Controls Ovarian Cancer Cell Proliferation

1 de August de 2017/in Viñals's lab/by miguel

Int J Mol Sci. 2017 Jul 30;18(8):1658. doi: 10.3390/ijms18081658. ABSTRACT There have been no major improvements in the overall survival of ovarian cancer patients in recent decades. Even though more accurate surgery and more effective treatments are available, the mortality rate remains high. Given the differences in origin and the heterogeneity of these tumors, research […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-08-01 10:00:002017-08-01 10:00:00TGFβ Controls Ovarian Cancer Cell Proliferation

Two-Dimensional Ultrasound Evaluation of the Fetal Cerebral Aqueduct: Improving the Antenatal Diagnosis and Counseling of Aqueductal Stenosis

24 de April de 2017/in Viñals's lab/by miguel

Fetal Diagn Ther. 2017;42(4):278-284. doi: 10.1159/000458439. Epub 2017 Apr 22. ABSTRACT OBJECTIVE: To describe a technique for the visualization and measurement of cerebral aqueduct diameter through a 2D sagittal median plane, and to report its aspect and measurement in fetuses with aqueductal stenosis (AS). METHODS: This was a cross-sectional study of 207 morphologically normal fetuses […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-04-24 10:00:002017-04-24 10:00:00Two-Dimensional Ultrasound Evaluation of the Fetal Cerebral Aqueduct: Improving the Antenatal Diagnosis and Counseling of Aqueductal Stenosis

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

20 de December de 2016/in Viñals's lab/by miguel

Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19. ABSTRACT Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-12-20 11:00:002016-12-20 11:00:00Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
Page 8 of 23«‹678910›»

Research Projects

– Ref: PID2020-117815RB-I00 Title: El perfil metabólico como una oportunidad terapéutica en el cáncer epitelial de ovario. implicaciones en metástasis y resistencia a los tratamientos. DGICYT, MINECO. 2021-2024. 217.800 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.

– Ref: SAF2017-85869-R Title: Mecanismos de señalización y control metabólico implicados en la diseminación y quimioresistencia en cáncer epitelial de ovario. DGICYT, MINECO. 2018-2020. 181.500 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.

Collaborations

Peter B. Vermeulen, University of Antwerp and GZA Hospitals, Belgium
Artur Mezheyeuski, VHIO, Barcelona
Pnina Brodt, Mc Gill University, Montreal, Canada
and Liver Metastases Research Network members

Viñals's lab
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Casanovas’ LabCasanovas's Lab
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}